Pelvis Adaptive Radiotherapy (ART)
Pelvis Adaptive radiotherapy (ART) is a two phase study looking at using adaptive radiotherapy to help reduce toxicity for cancer patients having radiotherapy in the pelvic region. Adaptive radiotherapy is a new technology that provides the ability to account for daily changes in anatomy. Adaptive radiotherapy also pro
| Condition(s) | Pelvis Neoplasms |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Pelvis Adaptive radiotherapy (ART) is a two phase study looking at using adaptive radiotherapy to help reduce toxicity for cancer patients having radiotherapy in the pelvic region. Adaptive radiotherapy is a new technology that provides the ability to account for daily changes in anatomy. Adaptive radiotherapy also provides a foundation for which radiotherapy margins might be safely reduced. Phase 1 of this study is looking to see if a radiation therapist centred adaptive workflow can be implemented. If phase 1 of this study is safe and feasible, the study will proceed to phase 2. Phase 2 of the study looks at using adaptive technology to reduce radiation treatment margins. The primary aim of this study is to see whether margin reduced treatment using adaptive radiotherapy can reduce side |
| Who can participate | Inclusion Criteria: 1. Age \> 18 2. ECOG performance status 0-2 3. Patients receiving curative or adjuvant pelvic radiation including: 1. Prostate cancer where nodal treatment is required 2. Prostate cancer post prostatectomy 3. Bladder cancer 4. Rectal cancer 5. Anal cancer 6. Adjuvant radiotherapy for gynaecological cancers 7. Pelvic Lymph nodes only 4. Ability to understand and the willingness to sign an informed consent Exclusion Criteria: * Hip prosthesis * Patient separation from approximate radiation centre to skin edge \> 24cm, measured on diagnostic scan |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Royal North Shore Hospital |
| Locations | St Leonards, New South Wales, Australia |
| Start date | 2025-10-09 |
| NCT ID | NCT06650033 |
| Official listing | https://clinicaltrials.gov/study/NCT06650033 |